title: The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma.
abstract: BACKGROUND
  Survival rates after resection of pancreatic adenocarcinoma are poor; however, several tumor-related prognostic factors have been identified. There is increasing evidence that additional patient-related prognostic factors, such as ongoing systemic inflammatory response, are associated with poor outcomes in patients with common solid tumors. The purpose of this study was to evaluate the prognostic significance of the modified glasgow prognostic score (mGPS) in resected pancreatic ductal adenocarcinoma.
  
  
  METHODS
  Data were collected from 101 patients who had undergone pancreatic resection for ductal adenocarcinoma. Tumor and host factors were analyzed by Kaplan-Meier and Cox proportional hazard models to evaluate their potential prognostic effects.
  
  
  RESULTS
  An elevated mGPS was associated with lower overall survival rate after pancreatic resection. The median actuarial survival rate for patients with an mGPS of 0, 1, or 2 was 37.2, 11.5, and 7.3, respectively (p = 0.0001). The Cox proportional hazards model, including all the parameters statistically significant at univariate analysis, demonstrated that mGPS, lymph node ratio (LNR), and positive resection margins were independent negative prognostic factors
  
  
  CONCLUSIONS
  Margin involvement, LNR, and the preoperative mGPS were identified as independent predictors of survival in patients undergoing potentially curative pancreatic resection. Based on the present results and existing validation literature, the mGPS should be included in the routine assessment of patients with pancreatic cancer to better stratify patients for entry into therapeutic trials.
authors.affiliation: Department of General Surgery, University of Rome La Sapienza, Rome, Italy. marco.latorre@uniroma1.it
authors.forename: Marco
authors.initials: M
authors.lastname: La Torre
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Nigri
authors.forename: Marco
authors.initials: M
authors.lastname: Cavallini
authors.forename: Paolo
authors.initials: P
authors.lastname: Mercantini
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Ziparo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ramacciato
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000556:secondary* / Q000601:surgery; D000368:Aged; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000473:pathology* / Q000601:surgery; D016577:Pancreaticoduodenectomy; D011379:Prognosis; D016016:Proportional Hazards Models; D012709:Serum Albumin / Q000378:metabolism*; D015996:Survival Rate
chemical_list: D012709:Serum Albumin; D002097:C-Reactive Protein